Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
POINT Biopharma Global Inc.
| Metric | POINT Biopharma Global Inc. Healthcare |
|---|---|
| Quality Score | 83 / 100 |
| Revenue (latest) | $227M |
| Net income (latest) | $98M |
| Operating margin | 55.4% |
| Net margin | 43.4% |
| Return on equity | 20.2% |
| Return on assets | 17.0% |
| Return on capital (ROCE) | 25.2% |
| Debt / equity | 0.19× |
| Revenue growth (YoY) | — |
| Altman Z″ (distress) | 12.39 |
| Accruals / assets | −14.7% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.